Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Pharmakon Compounding Pharmacy, Inc.
483
•Pharmakon Compounding Pharmacy, Inc.•May 6, 2016

Pharmakon Compounding Pharmacy, Inc. – FDA 483, May 6, 2016

Record Details

The FDA Form 483 details numerous deficiencies at a facility producing sterile drug products. Key issues include inadequate validation of sterilization processes and aseptic process simulations (media fills), with specific concerns about worst-case conditions, lot sizes, and container closure systems. Personnel performing aseptic processes, including technicians and pharmacists, were observed producing sterile lots (e.g., Epinephrine 1 mg/ml, Cefuroxime 10 mg/ml) without documented media fill validation.

Smoke studies for ISO 5 areas were found to be deficient, lacking documentation of dynamic conditions. Procedures for preventing microbiological contamination were not established or written. Observations during production of Epinephrine and Phenylephrine/Tropicamide included unsanitized non-sterile syringes, obstructed airflow in critical areas, and infrequent replacement of critical supplies.

Aseptic processing areas were deficient in maintaining equipment and environmental control. ISO 5 laminar flow hoods were located in unclassified rooms, increasing contamination risk, and their HEPA filters showed failures. Environmental monitoring was insufficient, not performed daily or under dynamic conditions, and media plates lacked disinfectant neutralizers.

Cleaning and disinfection procedures were inadequate, with no assessment of disinfectant efficacy or cleaning equipment suitability. Personnel garb was inappropriate, with non-sterile items and exposed skin observed in aseptic areas.

Drug product testing and release were severely deficient. Sterile products were released without potency testing (e.g., Epinephrine, Phenylephrine/Tropicamide, Lidocaine/Epinephrine

Company
Pharmakon Compounding Pharmacy, Inc.
Inspection date
May 6, 2016
Product type
Drugs
Office
Detroit District Office
People
  • Constantin Y. Philopoulos
  • Charles L. Zhou (Investigator)
View Company Profile

ID · 8a4580ee-df7c-4e42-a5a7-b13b6cfac286

Violation Codes3
21 CFR 21021 CFR 21121 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Pharmakon Compounding Pharmacy, Inc.
  • WARNING_LETTER - 2016-05-06May 6, 2016

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Pharmakon Compounding Pharmacy, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.